New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.
Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892–1868, USA. dunleavk@mail.nih.gov
Kieron
K
Dunleavy
Richard L
RL
Piekarz
Jasmine
J
Zain
John E
JE
Janik
Wyndham H
WH
Wilson
Owen A
OA
O'Connor
Susan E
SE
Bates
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000627:therapeutic use; D003585:Cell Biology; D032882:Comprehension; D055808:Drug Discovery / Q000379:methods / Q000639:trends; D020869:Gene Expression Profiling; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis* / Q000209:etiology* / Q000235:genetics / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods; D035703:Therapies, Investigational / Q000639:trends*
D000970:Antineoplastic Agents